Health Care [ 8/12 ] | Biotechnology [ 49/73 ]
NASDAQ | Common Stock
Innate PharmaS. A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited.
Innate PharmaS. A. was incorporated in 1999 and is based in Marseille, France.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 25 | -0.30 Decreased by N/A% | -0.40 Increased by +25.00% |
| Mar 27, 25 | -0.30 Decreased by N/A% | -0.40 Increased by +25.00% |
| Nov 13, 24 | 0.00 Decreased by N/A% | - |
| Sep 12, 24 | 0.00 Decreased by -100.00% | -0.38 Increased by +100.00% |
| May 14, 24 | 0.00 Decreased by N/A% | - |
| Mar 21, 24 | 0.00 Decreased by N/A% | -0.41 Increased by +100.00% |
| Nov 14, 23 | 0.00 Decreased by N/A% | - |
| Sep 14, 23 | 0.02 Increased by +N/A% | -0.14 Increased by +114.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 276.00 K Decreased by -97.43% | -24.71 M Decreased by -432.02% | Decreased by -8.95 K% Decreased by -20.57 K% |
| Jun 30, 24 | 12.35 M Decreased by -65.07% | -24.76 M Decreased by -1.54 K% | Decreased by -200.60% Decreased by -4.23 K% |
| Mar 31, 24 | 21.44 M Increased by +6.69% | -9.29 M Decreased by -1.18 K% | Decreased by -43.31% Decreased by -1.11 K% |
| Dec 31, 23 | 21.44 M Increased by +158.07% | -9.29 M Increased by +85.58% | Decreased by -43.31% Increased by +94.41% |
| Sep 30, 23 | 10.72 M Increased by +77.43% | -4.64 M Increased by +85.57% | Decreased by -43.31% Increased by +91.87% |
| Jun 30, 23 | 35.34 M Decreased by -14.36% | 1.72 M Decreased by -72.74% | Increased by +4.86% Decreased by -68.17% |
| Mar 31, 23 | 20.10 M Increased by +N/A% | 859.00 K Increased by +N/A% | Increased by +4.27% - |
| Dec 31, 22 | 8.31 M Increased by +197.49% | -64.41 M Decreased by -121.40% | Decreased by -775.14% Increased by +25.58% |